Stay updated on Pembrolizumab Post-ASCT in Lymphoma Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab Post-ASCT in Lymphoma Clinical Trial page.

Latest updates to the Pembrolizumab Post-ASCT in Lymphoma Clinical Trial page
- Check3 days agoNo Change Detected
- Check10 days agoChange DetectedThe page shows a revision from v3.4.2 to v3.4.3. This appears to be a minor update with no changes to study content.SummaryDifference0.1%

- Check17 days agoNo Change Detected
- Check32 days agoChange DetectedSite-level revision notes show Revision: v3.4.2 with dates 2026-01-26 and 2026-02-12, replacing v3.4.1; this does not affect the study data or core content. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

- Check39 days agoChange DetectedRevision updated from v3.4.0 to v3.4.1. No visible changes to study content or navigation.SummaryDifference0.1%

- Check61 days agoChange DetectedThe page now shows Revision: v3.3.4 and has removed Revision: v3.3.3, a minor metadata update that does not alter study details. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check83 days agoChange DetectedLocations section added, listing California, Massachusetts, New York, and Texas under a single Locations heading; old state-specific location blocks replaced. HHS Vulnerability Disclosure link removed.SummaryDifference0.5%

- Check112 days agoChange DetectedAdded a note that publications are automatically filled in from PubMed and may not be about the study, and updated the revision to v3.3.2.SummaryDifference0.1%

Stay in the know with updates to Pembrolizumab Post-ASCT in Lymphoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab Post-ASCT in Lymphoma Clinical Trial page.